Matthew M Grabowski
Overview
Explore the profile of Matthew M Grabowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kay K, Lee J, Hong E, Beilis J, Dayal S, Wesley E, et al.
J Clin Invest
. 2024 Nov;
135(2.
PMID: 39561012
The glioblastoma (GBM) microenvironment is enriched in immunosuppressive factors that potently interfere with the function of cytotoxic T lymphocytes. Cancer cells can directly affect the immune system, but the mechanisms...
2.
Jarmula J, Lee J, Lauko A, Rajappa P, Grabowski M, Dhawan A, et al.
Neurooncol Adv
. 2024 Sep;
6(1):vdae142.
PMID: 39233830
Primary central nervous system (CNS) tumors affect tens of thousands of patients each year, and there is a significant need for new treatments. Macrophage migration inhibitory factor (MIF) is a...
3.
Kay K, Lee J, Hong E, Beilis J, Dayal S, Wesley E, et al.
bioRxiv
. 2023 Nov;
PMID: 38014234
The glioblastoma microenvironment is enriched in immunosuppressive factors that potently interfere with the function of cytotoxic T lymphocytes. Cancer cells can directly impact the immune system, but the mechanisms driving...
4.
Kaisman-Elbaz T, Xiao T, Grabowski M, Barnett G, Mohammadi A
Neurosurgery
. 2023 Jul;
93(4):e112.
PMID: 37477434
No abstract available.
5.
Lee J, Nicosia M, Hong E, Silver D, Li C, Bayik D, et al.
Cancer Discov
. 2023 Jun;
13(9):2090-2105.
PMID: 37378557
Significance: Immunotherapies in patients with GBM have been unsuccessful due to a variety of factors, including the highly immunosuppressive tumor microenvironment in GBM. This study demonstrates that sex-biased T-cell behaviors...
6.
Alban T, Grabowski M, Otvos B, Bayik D, Wang W, Zalavadia A, et al.
JCI Insight
. 2023 May;
8(13).
PMID: 37252795
Intratumoral heterogeneity is a defining hallmark of glioblastoma, driving drug resistance and ultimately recurrence. Many somatic drivers of microenvironmental change have been shown to affect this heterogeneity and, ultimately, the...
7.
Grabowski M, Watson D, Chung K, Lee J, Bayik D, Lauko A, et al.
medRxiv
. 2023 Mar;
PMID: 36945620
Glioblastoma (GBM) treatment includes maximal safe resection of the core and MRI contrast-enhancing (CE) tumor. Complete resection of the infiltrative non-contrast-enhancing (NCE) tumor rim is rarely achieved. We established a...
8.
Kaisman-Elbaz T, Xiao T, Grabowski M, Barnett G, Mohammadi A
Neurosurgery
. 2023 Mar;
93(2):427-435.
PMID: 36861990
Background: Upfront laser interstitial thermal therapy (LITT) can be used as part of the treatment paradigm in difficult-to-access newly diagnosed glioblastoma multiforme (ndGBM) cases. The extent of ablation, though, is...
9.
Grabowski M, Srinivasan E, Vaios E, Sankey E, Otvos B, Krivosheya D, et al.
Neurooncol Adv
. 2022 Jul;
4(1):vdac086.
PMID: 35795470
Background: Improved survival for patients with brain metastases has been accompanied by a rise in tumor recurrence after stereotactic radiotherapy (SRT). Laser interstitial thermal therapy (LITT) has emerged as an...
10.
Lee J, Grabowski M, Lathia J
J Clin Invest
. 2022 Apr;
132(8).
PMID: 35426370
Given its aggressive natural history and immunosuppressive nature, glioblastoma (GBM) remains difficult to treat. Tumor Treating Fields (TTFields) are a promising treatment for GBM patients, yet the entirety of their...